PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS (NCT07142291)
A Phase IIB Randomized, Double-Blind, Placebo-Controlled, Multi-Dose Study to Evaluate the Effects of PHENOGENE-1A (Cromolyn) as an Adjuvant Treatment in Subjects With Mild to Moderate Amyotrophic Lateral Sclerosis (ALS)
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to test the effects of PHENOGENE-1A, which is the treatment under investigation in this study. This research will investigate if PHENOGENE-1A can help people with ALS by measuring their function using the ALS Functional Rating Scale Revised (ALSFRS-R), measuring lung function using pulmonary function tests (PFTs), such as forced vital capacity (FVC), and measuring neuro-inflammatory biomarkers in the blood.
Who can join: Review the eligibility criteria below.
Location: Honor Health Neurology - Bob Bove Neuroscience Institute — Scottsdale, Arizona
Age range: 18 Years to 75 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (22 Sites)
- Honor Health Neurology - Bob Bove Neuroscience Institute — Scottsdale, Arizona
- University of California San Diego — La Jolla, California
- Sutter Health - California Pacific Medical Center Research Institute — San Francisco, California
- Mayo Clinic Jacksonville — Jacksonville, Florida
- Lange Neurology — New York, New York
- NEUROHK s.r.o. — Hradec Králové,
- Fakultni Nemocnice Hradec Kralove — Hradec Králové,
- Thomayer University Hospital - Fakultni Thomayerova nemocnice — Prague,
- Charité Centrum für Neurologie, Neurochirurgie und Psychiatrie — Berlin,
- DIAKOVERE Henriettenstift - Klinik für Neurologie und Klinische Neurophysiologie — Hanover,
- Universitaetsklinikum Schleswig-Holstein — Lübeck,
- Michalski i Partnerzy Lekarze Spółka Partnerska — Krakow,
- SP ZOZ Szpital Uniwersytecki w Krakowie — Krakow,
- Centrum Medyczne NeuroProtect (NeuroProtect Medical Center) — Warsaw,
- City Clinic Research — Warsaw,
- University Clinical Center of Serbia — Belgrade,
- Hospital General Universitario Dr. Balmis de Alicante — Alicante,
- Barcelona Sea Hospital (Hospital Del Mar De Barcelona) — Barcelona,
- Hospital Universitario Vall D Hebron — Barcelona,
- Hospital Universitario Ramon Y Cajal — Madrid,
- Hospital Regional Universitario De Malaga — Málaga,
- Hospital Universitario Virgen Del Rocio — Seville,
📞 Contact the Study Coordinator
Phone: (617) 784-0490
Email: delmaleh@phenonet.us
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Amyotrophic Lateral Sclerosis (ALS)
- HEALEY ALS Platform Trial - Regimen I NUZ-001 — Boston, Massachusetts
- A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS) — La Jolla, California
- Efficacy and Safety of MSC-NTF (NurOwn) in Participants With Early Symptomatic ALS and Moderate Disease Presentation in ALS (ENDURANCE STUDY) — Phoenix, Arizona
- Resiliency Intervention for Patients With ALS and Their Care-Partners — Boston, Massachusetts
- Safety Study of XT-150 in Participants With ALS — Phoenix, Arizona
- A Phase Ⅰ/Ⅱa Study of SNUG01 in Adult Subjects With ALS — Boston, Massachusetts
Explore by condition: All Amyotrophic Lateral Sclerosis (ALS) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.